168 related articles for article (PubMed ID: 9621079)
21. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?
de Oliveira T; Engelbrecht S; Janse van Rensburg E; Gordon M; Bishop K; zur Megede J; Barnett SW; Cassol S
J Virol; 2003 Sep; 77(17):9422-30. PubMed ID: 12915557
[TBL] [Abstract][Full Text] [Related]
22. Specific reverse transcriptase slippage at the HIV ribosomal frameshift sequence: potential implications for modulation of GagPol synthesis.
Penno C; Kumari R; Baranov PV; van Sinderen D; Atkins JF
Nucleic Acids Res; 2017 Sep; 45(17):10156-10167. PubMed ID: 28973470
[TBL] [Abstract][Full Text] [Related]
23. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.
Myint L; Matsuda M; Matsuda Z; Yokomaku Y; Chiba T; Okano A; Yamada K; Sugiura W
Antimicrob Agents Chemother; 2004 Feb; 48(2):444-52. PubMed ID: 14742193
[TBL] [Abstract][Full Text] [Related]
24. Gag-Pol Transframe Domain p6* Is Essential for HIV-1 Protease-Mediated Virus Maturation.
Yu FH; Chou TA; Liao WH; Huang KJ; Wang CT
PLoS One; 2015; 10(6):e0127974. PubMed ID: 26030443
[TBL] [Abstract][Full Text] [Related]
25. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
[TBL] [Abstract][Full Text] [Related]
26. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
27. Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy.
Ibe S; Shibata N; Utsumi M; Kaneda T
Microbiol Immunol; 2003; 47(1):71-9. PubMed ID: 12636256
[TBL] [Abstract][Full Text] [Related]
28. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
[TBL] [Abstract][Full Text] [Related]
29. Morphogenic capabilities of human immunodeficiency virus type 1 gag and gag-pol proteins in insect cells.
Hughes BP; Booth TF; Belyaev AS; McIlroy D; Jowett J; Roy P
Virology; 1993 Mar; 193(1):242-55. PubMed ID: 8438569
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
Karacostas V; Wolffe EJ; Nagashima K; Gonda MA; Moss B
Virology; 1993 Apr; 193(2):661-71. PubMed ID: 7681610
[TBL] [Abstract][Full Text] [Related]
31. A basis for new approaches to the chemotherapy of AIDS: novel genes in HIV-1 potentially encode selenoproteins expressed by ribosomal frameshifting and termination suppression.
Taylor EW; Ramanathan CS; Jalluri RK; Nadimpalli RG
J Med Chem; 1994 Aug; 37(17):2637-54. PubMed ID: 8064794
[TBL] [Abstract][Full Text] [Related]
32. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.
Zennou V; Mammano F; Paulous S; Mathez D; Clavel F
J Virol; 1998 Apr; 72(4):3300-6. PubMed ID: 9525657
[TBL] [Abstract][Full Text] [Related]
33. A p6Pol-protease fusion protein is present in mature particles of human immunodeficiency virus type 1.
Almog N; Roller R; Arad G; Passi-Even L; Wainberg MA; Kotler M
J Virol; 1996 Oct; 70(10):7228-32. PubMed ID: 8794372
[TBL] [Abstract][Full Text] [Related]
34. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
Doyon L; Croteau G; Thibeault D; Poulin F; Pilote L; Lamarre D
J Virol; 1996 Jun; 70(6):3763-9. PubMed ID: 8648711
[TBL] [Abstract][Full Text] [Related]
35. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
[TBL] [Abstract][Full Text] [Related]
36. Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.
Leiherer A; Ludwig C; Wagner R
J Virol; 2009 Jul; 83(14):7210-20. PubMed ID: 19403679
[TBL] [Abstract][Full Text] [Related]
37. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
[TBL] [Abstract][Full Text] [Related]
38. Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
Rossi AH; Rocco CA; Mangano A; Sen L; Aulicino PC
AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1056-60. PubMed ID: 23458243
[TBL] [Abstract][Full Text] [Related]
39. C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.
Yu FH; Huang KJ; Wang CT
J Virol; 2017 May; 91(10):. PubMed ID: 28250114
[TBL] [Abstract][Full Text] [Related]
40. Deciphering the role of the Gag-Pol ribosomal frameshift signal in HIV-1 RNA genome packaging.
Nikolaitchik OA; Hu WS
J Virol; 2014 Apr; 88(8):4040-6. PubMed ID: 24453371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
